{"id":68219,"date":"2026-06-15T21:43:56","date_gmt":"2026-06-15T13:43:56","guid":{"rendered":"https:\/\/flcube.com\/?p=68219"},"modified":"2026-06-15T21:43:57","modified_gmt":"2026-06-15T13:43:57","slug":"simcere-pharmaceutical-partners-with-stanford-university-to-develop-first-in-class-ipf-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68219","title":{"rendered":"Simcere Pharmaceutical Partners with Stanford University to Develop First-in-Class IPF Therapy"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Simcere Pharmaceutical Group (<a href=\"https:\/\/www.google.com\/finance\/quote\/2096:HKG\">HKG: 2096<\/a>)<\/strong> announced a <strong>collaborative research agreement<\/strong> with <strong>Stanford University School of Medicine<\/strong> to jointly advance an <strong>exploratory study in the respiratory field<\/strong>, specifically targeting the development of <strong>innovative therapies for idiopathic pulmonary fibrosis (IPF)<\/strong>. The partnership grants Simcere exclusive global rights to a first-in-class molecule upon successful development.<\/p>\n\n\n\n<h2 id=\"h-partnership-structure\" class=\"wp-block-heading\">Partnership Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Academic Partner<\/strong><\/td><td>Stanford University School of Medicine<\/td><\/tr><tr><td><strong>Research Leaders<\/strong><\/td><td>Dr. Chaitan Khosla and Dr. Bianxiao Cui (Stanford Innovative Medicines Accelerator)<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Idiopathic pulmonary fibrosis (IPF)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Exploratory research<\/td><\/tr><tr><td><strong>Molecule Type<\/strong><\/td><td>First-in-class therapeutic candidate<\/td><\/tr><tr><td><strong>Funding<\/strong><\/td><td>Fully funded by Simcere Pharmaceutical<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-intellectual-property-amp-commercial-rights\" class=\"wp-block-heading\">Intellectual Property &amp; Commercial Rights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>License Type:<\/strong> Exclusive worldwide license<\/li>\n\n\n\n<li><strong>Rights Scope:<\/strong> 100% global commercial rights upon successful development<\/li>\n\n\n\n<li><strong>Territory:<\/strong> Worldwide without geographical restrictions<\/li>\n\n\n\n<li><strong>Development Risk:<\/strong> Simcere assumes full development costs and regulatory pathway responsibilities<\/li>\n\n\n\n<li><strong>Academic Contribution:<\/strong> Stanford provides scientific expertise and laboratory infrastructure<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale\" class=\"wp-block-heading\">Strategic Rationale<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This collaboration leverages <strong>Stanford&#8217;s world-leading chemical biology expertise<\/strong> through the laboratories of <strong>Dr. Chaitan Khosla<\/strong> (renowned for polyketide synthase research and celiac disease therapeutics) and <strong>Dr. Bianxiao Cui<\/strong> (pioneer in nanobiotechnology and single-molecule biophysics). The partnership aligns with Simcere&#8217;s strategy to access cutting-edge academic innovation while securing comprehensive global commercial rights.<\/p>\n\n\n\n<h2 id=\"h-ipf-market-context-amp-unmet-need\" class=\"wp-block-heading\">IPF Market Context &amp; Unmet Need<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Disease Burden:<\/strong> IPF affects approximately 3 million people globally with median survival of 3-5 years post-diagnosis<\/li>\n\n\n\n<li><strong>Current Therapies:<\/strong> Limited to pirfenidone and nintedanib, which slow but do not halt disease progression<\/li>\n\n\n\n<li><strong>Market Size:<\/strong> Global IPF therapeutics market projected to reach <strong>$4.5 billion by 2028<\/strong><\/li>\n\n\n\n<li><strong>Innovation Gap:<\/strong> Significant unmet need for disease-modifying or curative approaches<\/li>\n\n\n\n<li><strong>China Opportunity:<\/strong> Growing IPF diagnosis rates and expanding specialty care infrastructure<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-analysis\" class=\"wp-block-heading\">Competitive Landscape Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>First-in-Class Potential<\/strong><\/td><td>Opportunity to establish new standard of care if mechanism proves superior<\/td><\/tr><tr><td><strong>Global Rights<\/strong><\/td><td>Enables worldwide commercialization without licensing complexities<\/td><\/tr><tr><td><strong>Academic Innovation<\/strong><\/td><td>Access to novel target discovery and validation approaches<\/td><\/tr><tr><td><strong>Development Timeline<\/strong><\/td><td>Early-stage exploratory research suggests 5-7 year path to potential approval<\/td><\/tr><tr><td><strong>Risk Profile<\/strong><\/td><td>High scientific risk balanced by substantial commercial upside<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications-for-simcere\" class=\"wp-block-heading\">Strategic Implications for Simcere<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This partnership represents a significant expansion of Simcere&#8217;s <strong>respiratory therapeutic focus<\/strong> beyond its current oncology and CNS pipeline. By securing <strong>100% global rights<\/strong>, Simcere positions itself to potentially become a leader in IPF treatment, similar to its ambitions in other specialty therapeutic areas.<\/p>\n\n\n\n<h2 id=\"h-implementation-amp-next-steps\" class=\"wp-block-heading\">Implementation &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Research Initiation:<\/strong> Immediate commencement of exploratory studies at Stanford laboratories<\/li>\n\n\n\n<li><strong>Milestone Tracking:<\/strong> Defined scientific and development milestones to guide progression decisions<\/li>\n\n\n\n<li><strong>Regulatory Strategy:<\/strong> Early engagement with FDA and NMPA on potential accelerated pathways<\/li>\n\n\n\n<li><strong>Commercial Planning:<\/strong> Parallel market assessment and launch preparation activities<\/li>\n\n\n\n<li><strong>Portfolio Integration:<\/strong> Coordination with Simcere&#8217;s existing respiratory and fibrosis research programs<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-broader-industry-context\" class=\"wp-block-heading\">Broader Industry Context<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This deal exemplifies the growing trend of <strong>Chinese pharmaceutical companies partnering with elite U.S. academic institutions<\/strong> to access breakthrough science while maintaining full commercial control. The structure\u2014where the sponsor obtains complete global rights\u2014reflects increasing sophistication in international research collaborations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding research collaborations, development timelines, and commercial expectations. Actual results may differ due to risks including scientific feasibility, development challenges, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simcere Pharmaceutical Group (HKG: 2096) announced a collaborative research agreement with Stanford University School of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[1099,271],"class_list":["post-68219","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-2096","tag-simcere-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Simcere Pharmaceutical Partners with Stanford University to Develop First-in-Class IPF Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Simcere Pharmaceutical Group (HKG: 2096) announced a collaborative research agreement with Stanford University School of Medicine to jointly advance an exploratory study in the respiratory field, specifically targeting the development of innovative therapies for idiopathic pulmonary fibrosis (IPF). The partnership grants Simcere exclusive global rights to a first-in-class molecule upon successful development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68219\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simcere Pharmaceutical Partners with Stanford University to Develop First-in-Class IPF Therapy\" \/>\n<meta property=\"og:description\" content=\"Simcere Pharmaceutical Group (HKG: 2096) announced a collaborative research agreement with Stanford University School of Medicine to jointly advance an exploratory study in the respiratory field, specifically targeting the development of innovative therapies for idiopathic pulmonary fibrosis (IPF). The partnership grants Simcere exclusive global rights to a first-in-class molecule upon successful development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68219\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T13:43:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-15T13:43:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68219#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68219\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Simcere Pharmaceutical Partners with Stanford University to Develop First-in-Class IPF Therapy\",\"datePublished\":\"2026-06-15T13:43:56+00:00\",\"dateModified\":\"2026-06-15T13:43:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68219\"},\"wordCount\":516,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 2096\",\"Simcere Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68219#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68219\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68219\",\"name\":\"Simcere Pharmaceutical Partners with Stanford University to Develop First-in-Class IPF Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-15T13:43:56+00:00\",\"dateModified\":\"2026-06-15T13:43:57+00:00\",\"description\":\"Simcere Pharmaceutical Group (HKG: 2096) announced a collaborative research agreement with Stanford University School of Medicine to jointly advance an exploratory study in the respiratory field, specifically targeting the development of innovative therapies for idiopathic pulmonary fibrosis (IPF). The partnership grants Simcere exclusive global rights to a first-in-class molecule upon successful development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68219#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68219\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68219#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Simcere Pharmaceutical Partners with Stanford University to Develop First-in-Class IPF Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Simcere Pharmaceutical Partners with Stanford University to Develop First-in-Class IPF Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Simcere Pharmaceutical Group (HKG: 2096) announced a collaborative research agreement with Stanford University School of Medicine to jointly advance an exploratory study in the respiratory field, specifically targeting the development of innovative therapies for idiopathic pulmonary fibrosis (IPF). The partnership grants Simcere exclusive global rights to a first-in-class molecule upon successful development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68219","og_locale":"en_US","og_type":"article","og_title":"Simcere Pharmaceutical Partners with Stanford University to Develop First-in-Class IPF Therapy","og_description":"Simcere Pharmaceutical Group (HKG: 2096) announced a collaborative research agreement with Stanford University School of Medicine to jointly advance an exploratory study in the respiratory field, specifically targeting the development of innovative therapies for idiopathic pulmonary fibrosis (IPF). The partnership grants Simcere exclusive global rights to a first-in-class molecule upon successful development.","og_url":"https:\/\/flcube.com\/?p=68219","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-15T13:43:56+00:00","article_modified_time":"2026-06-15T13:43:57+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68219#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68219"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Simcere Pharmaceutical Partners with Stanford University to Develop First-in-Class IPF Therapy","datePublished":"2026-06-15T13:43:56+00:00","dateModified":"2026-06-15T13:43:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68219"},"wordCount":516,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 2096","Simcere Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68219#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68219","url":"https:\/\/flcube.com\/?p=68219","name":"Simcere Pharmaceutical Partners with Stanford University to Develop First-in-Class IPF Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-15T13:43:56+00:00","dateModified":"2026-06-15T13:43:57+00:00","description":"Simcere Pharmaceutical Group (HKG: 2096) announced a collaborative research agreement with Stanford University School of Medicine to jointly advance an exploratory study in the respiratory field, specifically targeting the development of innovative therapies for idiopathic pulmonary fibrosis (IPF). The partnership grants Simcere exclusive global rights to a first-in-class molecule upon successful development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68219#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68219"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68219#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Simcere Pharmaceutical Partners with Stanford University to Develop First-in-Class IPF Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68219","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68219"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68219\/revisions"}],"predecessor-version":[{"id":68220,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68219\/revisions\/68220"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68219"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68219"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68219"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}